Downloadable Resources | LIVTENCITY® (maribavir)

Resources

FOR YOU
FOR YOUR PATIENTS

Resources to help start your patient on LIVTENCITY^® (maribavir)

Start Form

DOWNLOAD

Healthcare Provider Checklist

Reference when completing the Start Form for detailed instructions and common errors.

DOWNLOAD

Quick Start Postcard

Helps eligible patients who are experiencing insurance delays get immediate access to 7 days of LIVTENCITY^®¶§ (maribavir)

^¶Must meet eligibility requirements.

^§Additional terms and conditions may apply.

DOWNLOAD

Sample Formulary Exception Letter

Customize this template if you need to submit a letter to your patient's insurance provider in the case of coverage rejection.

DOWNLOAD

Sample Letter of Medical Necessity

Customize this template if you need to submit a Letter of Medical Necessity to your patient’s insurance provider.

DOWNLOAD

Full Prescribing Information

Explore the Full Prescribing Information for LIVTENCITY^® (maribavir), available in English and Spanish.

DOWNLOAD

DESCARGAR

Resources to help your patients learn more about LIVTENCITY^® (maribavir)

LIVTENCITY^® (maribavir) Patient Brochure

This brochure helps patients and caregivers learn more about CMV and LIVTENCITY^® (maribavir).

The brochure is available in English and Spanish.

DOWNLOAD

DESCARGAR

Full Prescribing Information

Patients can explore the Full Prescribing Information for LIVTENCITY^® (maribavir), available in English and Spanish.

DOWNLOAD

DESCARGAR

Need support with your patient’s access or starting treatment with LIVTENCITY^® (maribavir)?

Contact Takeda Patient Support at 1-855-268-1825 (Monday–Friday, 8 AM–8 PM ET)

Connect with a Takeda Transplant Account Manager in your area

SEE THE SAFETY PROFILE

IMPORTANT SAFETY INFORMATION

Risk of Reduced Antiviral Activity When Co-administered with Ganciclovir and Valganciclovir

LIVTENCITY may antagonize the antiviral activity of ganciclovir and valganciclovir by inhibiting human CMV pUL97 kinase, which is required for activation/phosphorylation of ganciclovir and valganciclovir. Coadministration of LIVTENCITY with ganciclovir or valganciclovir is not recommended.

Virologic Failure During Treatment and Relapse Post-Treatment

Virologic failure due to resistance can occur during and after treatment with LIVTENCITY. Virologic relapse during the posttreatment period usually occurred within 4-8 weeks after treatment discontinuation. Some maribavir pUL97 resistance-associated substitutions confer cross-resistance to ganciclovir and valganciclovir. Monitor CMV DNA levels and check for maribavir resistance if the patient is not responding to treatment or relapses.

Risk of Adverse Reactions or Loss of Virologic Response Due to Drug Interactions

The concomitant use of LIVTENCITY and certain drugs may result in potentially significant drug interactions, some of which may lead to reduced therapeutic effect of LIVTENCITY or adverse reactions of concomitant drugs. Consider the potential for drug interactions prior to and during LIVTENCITY therapy; review concomitant medications during LIVTENCITY therapy and monitor for adverse reactions. Refer to the full prescribing information of LIVTENCITY for important drug interactions.

Maribavir is primarily metabolized by CYP3A4. Drugs that are strong inducers of CYP3A4 are expected to decrease maribavir plasma concentrations and may result in reduced virologic response; therefore, coadministration of LIVTENCITY with these drugs is not recommended, except for selected anticonvulsants.

Use with Immunosuppressant Drugs

LIVTENCITY has the potential to increase the drug concentrations of immunosuppressant drugs that are CYP3A and/or P-gp substrates where minimal concentration changes may lead to serious adverse events (including tacrolimus, cyclosporine, sirolimus and everolimus). Frequently monitor immunosuppressant drug levels throughout treatment with LIVTENCITY, especially following initiation and after discontinuation of LIVTENCITY and adjust immunosuppressant dose, as needed.

Adverse Reactions

The most common adverse events (all grades,> 10%) in subjects treated with LIVTENCITY were taste disturbance, nausea, diarrhea, vomiting, and fatigue.

INDICATION

LIVTENCITY is indicated for the treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet.

Please click for Full Prescribing Information.

IMPORTANT SAFETY INFORMATION

Risk of Reduced Antiviral Activity When Co-administered with Ganciclovir and Valganciclovir

Virologic Failure During Treatment and Relapse Post-Treatment

Risk of Adverse Reactions or Loss of Virologic Response Due to Drug Interactions

Use with Immunosuppressant Drugs

Adverse Reactions

The most common adverse events (all grades,> 10%) in subjects treated with LIVTENCITY were taste disturbance, nausea, diarrhea, vomiting, and fatigue.

INDICATION

Please click for Full Prescribing Information.

Need support with your patient’s access or starting treatment with LIVTENCITY® (maribavir)?

Need support with your patient’s access or starting treatment with LIVTENCITY^® (maribavir)?